Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. rivelin-clo

RIVELIN-CLO SIGNED

The Ultimate Therapy for the Oral Lichen Planus

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RIVELIN-CLO project word cloud

Explore the words cloud of the RIVELIN-CLO project. It provides you a very rough idea of what is the project "RIVELIN-CLO" about.

tissues    lichen    patch    spread    self    cure    market    exclusively    potentially    lives    painful    7    chance    erosive    venture    suffering    disorder    topical    staff    10m    generate    occlusion    sensations    diseases    patients    struggle    share    prevented    lack    iib    rivelin    founded    chronic    company    ultimately    trials    worldwide    daily    combined    commercial    correct    revenues    generating    lower    lesions    financial    mucosa    usa    treatment    markets    olp    employees    undesired    systemic    corticosteroids    damage    people    toxicity    afyx    gather    minimization    22    burning    approved    electrospinning    efficacy    living    first    options    hospitals    involve    alleviation    guarantee    therapeutic    kept    time    ip    2014    launching    planus    therapeutics    symptoms    lesion    immune    bystander    goals    ways    saliva    drug    normal    mucosal    adherence    international    clobetasol    innovative    84m    primary    oral    perspectives    causing    precancerous    treat    clo    incorporating    reg    dosing    ongoing    launch    6m    clinical    clinics    danish    2h   

Project "RIVELIN-CLO" data sheet

The following table provides information about the project.

Coordinator		 AFYX THERAPEUTICS A/S 

Organization address
address: LERGRAVSVEJ 57, 2TV.
city: COPENHAGEN
postcode: 2300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Denmark [DK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AFYX THERAPEUTICS A/S DK (COPENHAGEN) coordinator 50˙000.00

Map

 Project objective

Oral lichen planus (OLP) is an immune-related disorder affecting 84M people worldwide (10M in EU and USA). OLP is a chronic condition which can ultimately lead to precancerous lesions, while patients suffering from it may struggle daily with painful and/or burning sensations in the oral mucosa, being thus kept from living their normal lives. Since there is no approved cure for OLP, the primary goals of its treatment are the alleviation of symptoms and the minimization of mucosal damage from erosive lesions. Current therapeutic options involve the use of topical corticosteroids (typically Clobetasol). However, the ways of use available in the market show lack of adherence to the mucosa and there is a high chance that the product is spread to other areas (which results in reduced efficacy and potentially causing undesired topical and systemic side effects). Our Danish company AFYX Therapeutics A/S was founded in 2014 with the aim to develop innovative approaches to treat mucosal diseases such as OLP. We have developed our first product incorporating an innovative technology (using an electrospinning process): the RIVELIN®-CLO patch. It’s the first to have been developed exclusively for the treatment of OLP, and its unique properties include self-adherence to the oral tissues (2h of topical drug application); occlusion of the lesion; lower bystander toxicity (Clobetasol is prevented from being spread by saliva) and the correct dosing every time. Clinical Phase IIb trials of the patch are ongoing with clinics and hospitals across EU and US and through this project we aim to guarantee that RIVELIN®-CLO is a success from a technical, commercial and financial perspectives, before launching it to the international markets. Five years after market launch, we expect to gather 7% of the EU and US combined OLP treatment market share, generating €22.6M revenues to our company and increasing our staff to 40 employees and generate new IP to venture new markets with our technology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RIVELIN-CLO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RIVELIN-CLO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More